ReviewAmerican journal of cancer research2022
Emerging role of competing endogenous RNA and associated noncoding RNAs in thyroid cancer.
Review in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- LncRNA SLC7A11AR promotes lung adenocarcinoma progression by inhibiting ferroptosis via promoting SLC7A11 expression.International journal of biological sciences · 2025Article
- CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1.Cancer biology & therapy · 2024Article
- Cuproptosis-related ceRNA axis triggers cell proliferation and cell cycle through CBX2 in lung adenocarcinoma.BMC pulmonary medicine · 2024Article
- A Review and In Silico Analysis of Tissue and Exosomal Circular RNAs: Opportunities and Challenges in Thyroid Cancer.Cancers · 2022Review
- Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential.Biomolecules · 2022Review
- Crosstalk among long non-coding RNA, tumor-associated macrophages and small extracellular vesicles in tumorigenesis and dissemination.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of the thyroid is the most common endocrine malignancy. While treatment options are limited for individuals with medullary or anaplastic thyroid cancer, understanding the underlying mechanisms is vital to developing a successful thyroid cancer treatment strategy due to the tumor's multistep carcinogenesis. Non-coding RNAs (ncRNAs) have been associated with thyroid cancer progression in several recent studies; however, the role of regulatory interactions among different types of ncRNAs in thyroid cancer remains unclear. Recently, competing endogenous RNA (ceRNA) has been discovered as a mechanism demonstrating regulatory interactions among non-coding RNAs, including pseudogenes, long non-coding RNAs (lnRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs). It has been concluded from the literature that numerous ceRNA networks are deregulated during the development, invasion, and metastasis of thyroid cancer, as well as in epithelial-mesenchymal transition (EMT) and drug resistance. Further understanding of these deregulations is important to develop diagnostic procedures for early detection of thyroid cancer and promising therapeutic options for effective treatment. The purpose of this review is to highlight the emerging roles of some newly found ceRNA members in thyroid cancer and outline the current body of knowledge regarding ceRNA, lncRNA, pseudogenes, and miRNAs.
Indexed as
Identifiers
35411240PMC8984881W4226225569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.